Litigation Details for Eagle Pharmaceuticals, Inc. v. Slayback Pharma LLC (D. Del. 2018)
✉ Email this page to a colleague
Eagle Pharmaceuticals, Inc. v. Slayback Pharma LLC (D. Del. 2018)
| Docket | ⤷ Try a Trial | Date Filed | 2018-12-10 |
| Court | District Court, D. Delaware | Date Terminated | 2019-05-09 |
| Cause | 35:271 Patent Infringement | Assigned To | Colm Felix Connolly |
| Jury Demand | None | Referred To | |
| Parties | EAGLE PHARMACEUTICALS, INC. | ||
| Patents | 10,010,533; 9,265,831; 9,572,796; 9,572,797 | ||
| Attorneys | Nathan Roger Hoeschen | ||
| Firms | Smith, Katzenstein, & Jenkins LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Eagle Pharmaceuticals, Inc. v. Slayback Pharma LLC
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial and ⤷ Try a Trial .
Details for Eagle Pharmaceuticals, Inc. v. Slayback Pharma LLC (D. Del. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-12-10 | 1 | Complaint | (“the ’797 patent”); and 10,010,533 (“the ’533 patent”) (collectively, “the Patents-in-Suit”). …COUNT IV – INFRINGEMENT OF U.S. PATENT NO. 10,010,533 UNDER 35 U.S.C. § 271(e)(2) … INFRINGEMENT OF U.S. PATENT NO. 10,010,533 94. Eagle incorporates…infringement of the ’831 patent, the ’796 patent, the ’797 patent, and the ’533 patent. (b…of Eagle’s U.S. Patent Nos. 9,265,831 (“the ’831 patent”); 9,572,796 (“the ’796 patent”); 9,572,797 (“ | External link to document |
| 2019-01-10 | 17 | Redacted Document | (“the ‘797 patent”); and 10,010,533 (“the ‘533 patent”) (collectively, the “patents-in-suit”), which …infringes U.S. Patent Nos. 9,265,831 (“the ‘831 patent”); 9,572,796 (“the ‘796 patent”); 9,572,797 (“… the patents-in-suit. Rather, Plaintiff’s complaint alleges that Slayback infringes the patents-in-suit…infringe any claim of the patents-in-suit. All of the independent claims of these patents require a pharmaceutically…equivalents to prove infringement of the patents-in-suit. “[W]hen a patent drafter discloses but declines to | External link to document |
| 2019-02-11 | 23 | Redacted Document | “’831 Patent”); 9,572,796 (the “’796 Patent”); 9,572,797 (the “’797 Patent”); and 10,010,533 (the “’… four patents listed in the Orange Book and covering the formulation of Belrapzo®. U.S. Patents 9,265,831…“’533 Patent”) (the “Patents-in-Suit”) list inventors Nagesh Palepu and Philip Buxton. Certain claims…Plaintiff Plausibly Pled that Slayback Infringes the Patents-in-Suit............8 3. … questions over the proper interpretation of a patent’s intrinsic record are “not suitable” and “particularly | External link to document |
| 2019-05-09 | 28 | Memorandum Opinion | the "#796 patent"), 9,572,797 (the "#797 patent"), and 10,010,533 (the "#533…equivalents of four patents: U.S. Patent Nos. 9,265,831 (the "#831 patent"), 9,572,796 …glycol in embodiments of the patented invention. See, e.g., #796 patent at 1:60-64, 4:34-47, 5:27-35,…;#533 patent"). See generally D.I. 1. Pending before me is Slayback's motion for judgment…manufacture and sell before the four asserted patents expire a bendamustine drug that is bioequivalent | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
